When the pro-inflammatory pair, a receptor called CCR2 and its ligand CCL-2, get together, it increases the risk of developing type 1 diabetes, scientists report.
Researchers discuss the ability of some microalgae metabolites to prevent cytokine storm syndrome during COVID-19.
A recent article provided a review of a study led by academician Zhong Nanshan, in China, on COVID-19 treatment by inhalation of a mixed gas composed of hydrogen and oxygen.
Studying mice, researchers at Washington University School of Medicine in St. Louis have developed a method of stem cell transplantation that does not require radiation or chemotherapy.
Type 1 diabetes, rheumatoid arthritis, and cancer are just some of the disorders associated with specific genes not “turning on” and “turning off” as they should.
Global effort focuses on developing better methods to quantify joint damage in rheumatoid arthritis patients
Crowdsourcing has become an increasingly popular way to develop machine learning algorithms to address many clinical problems in a variety of illnesses.
New data from a research team at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) shows how inflammatory reactions can be resolved by changes to the metabolism of macrophages.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that people with chronic inflammatory diseases, such as rheumatoid arthritis (RA), who take immunosuppressive therapy appear to have an impaired immunity response to SARS-CoV-2, the coronavirus that causes COVID-19, vaccines. Patients currently on glucocorticoids or B-cell depleting therapy appear […]
Cycling JAK inhibitors can be effective for treating people with difficult-to-treat rheumatoid arthritis
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that people with difficult-to-treat rheumatoid arthritis who do not have success with one Janus kinase inhibitor (JAK inhibitor) can achieve success either cycling to other JAKi medications or switching to a biologic drug.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that in one study, the majority of rheumatoid arthritis patients on an ultra-low dose of the drug rituximab maintained low disease activity for up to four years, and rarely needed to switch to other biologic drugs or glucocorticoids to […]